Large porous particles for pulmonary drug delivery

Science

Volumn 276, Issue 5320, 1997, Pages 1868-1871

  Edwards, David A ^a   Hanes, Justin ^b   Caponetti, Giovanni ^b,c   Hrkach, Jeffrey ^b   Ben Jebria, Abdelaziz ^a   Eskew, Mary Lou ^d   Mintzes, Jeffrey ^a   Deaver, Daniel ^d   Lotan, Noah ^e   Langer, Robert ^b  

^a The Pennsylvania State University   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c UNIVERSITY OF PARMA   (Italy)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; POLYGLACTIN; TESTOSTERONE;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EMULSION; ENCAPSULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG LAVAGE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; BRONCHOALVEOLAR LAVAGE; DRUG CARRIERS; DRUG COMPOUNDING; INSULIN; LACTIC ACID; LUNG; MALE; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYLYSINE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 10744227569     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5320.1868     Document Type: Article

References (40)

1. O. Einarsson et al., Ann. N.Y. Acad. Sci. 762, 89 (1995).
2. R. Niven, Crit. Rev. Ther. Drug Carrier Syst. 12, 151 (1995).
3. S. J. Smith and J. A. Bernstein, in Inhalation Aerosols, A. J. Hickey, Ed. (Dekker, New York, 1996), pp. 233-269.
4. J. S. Patton and R. M. Platz, Adv. Drug Delivery Rev. 8, 179 (1992).
5. I. Gonda, in Topics in Pharmaceutical Sciences 1991, D. J. A. Crommelin and K. K. Midha, Eds. (Medpharm Scientific, Stuttgart, 1992), pp. 95-115.
6. R. Langer, Science 249, 1527 (1990).
7. I. Gonda, Crit. Rev. Ther. Drug Carrier Syst. 6, 4273 (1990).
8. D. Pavia, in Aerosols and the Lung: Clinical and Experimental Aspects, S. W. Clarke and D. Pavia, Eds. (Butterworths, London, 1984), pp. 200-229.
9. M. B. Warheit and M. A. Hartsky, Microscopy Res. Tech. 26, 412 (1993); J. D. Brain, in The Reticuloendothelial System, S. M. Reichard and J. Filkins, Eds. (Plenum, New York, 1985), pp. 315-331.
10. M. B. Warheit and M. A. Hartsky, Microscopy Res. Tech. 26, 412 (1993); J. D. Brain, in The Reticuloendothelial System, S. M. Reichard and J. Filkins, Eds. (Plenum, New York, 1985), pp. 315-331.
11. D. Ganderton, J. Biopharm. Sci. 3, 101 (1992); A. Adjei and J. Garren, Pharm. Res. 7, 565 (1990).
12. D. Ganderton, J. Biopharm. Sci. 3, 101 (1992); A. Adjei and J. Garren, Pharm. Res. 7, 565 (1990).
13. 3 have been prepared by the double-emulsification technique [R. Jeyanthi, B. C. Thanoo, R. C. Metha, P. P. DeLuca, J. Controlled Release 38, 235 (1996)], although these microspheres, at 35 to 140 μm, were inappropriately large for deep-lung inhalation. PLAL-Lys particles were also made using the single-emulsification technique [J. S. Hrkach, J. Ou, N. Lotan, R. Langer, Macromolecules 28, 4736 (1995)]; these particles, apparently because of the cationic charge of the graft copolymer, are highly porous even when prepared by the single-emulsification method.
14. 3 have been prepared by the double-emulsification technique [R. Jeyanthi, B. C. Thanoo, R. C. Metha, P. P. DeLuca, J. Controlled Release 38, 235 (1996)], although these microspheres, at 35 to 140 μm, were inappropriately large for deep-lung inhalation. PLAL-Lys particles were also made using the single-emulsification technique [J. S. Hrkach, J. Ou, N. Lotan, R. Langer, Macromolecules 28, 4736 (1995)]; these particles, apparently because of the cationic charge of the graft copolymer, are highly porous even when prepared by the single-emulsification method.
15. 3.
16. We placed 20 mg of porous or nonporous microparticles, with encapsulated rhodamine as a fluorescent marker, in No. 1 hard gelatin capsules (Eli Lilly), loaded the capsules into a Spinhaler DPI (Fisons, Bedford, MA), and activated the DPI. Particles were aerosolized into a Mark I Andersen Impactor (Andersen Samplers, Atlanta, GA) from the Spinhaler device for 30 s at a flow rate of 28.3 liter/min. [Each plate of the impactor was previously coated with Tween 80 by immersing the plates in an acetone solution (5% w/v) and then evaporating the acetone in an oven at 60°C for 5 min.] After aerosolization and deposition, particles were collected from each stage of the impactor system and completely degraded in NaOH solution (0.2 N). After incubation at 37°C for 12 hours, the fluorescence of each solution was measured (wavelengths of 554 nm excitation, 574 nm emission).
17. aer of 1.57 ± 2.41 μm for the porous particles and 5.82 ± 1.86 μm for the nonporous particles. Using Eq. 1 in (12), this indirectly yields a mass density ratio (porous to nonporous) of 0.1 ± 0.3. Given that the measured ratio of mass densities is 0.11 (Fig. 2), mass density variation within the two powders appears to be small (<10%).
18. aer of 1.57 ± 2.41 μm for the porous particles and 5.82 ± 1.86 μm for the nonporous particles. Using Eq. 1 in (12), this indirectly yields a mass density ratio (porous to nonporous) of 0.1 ± 0.3. Given that the measured ratio of mass densities is 0.11 (Fig. 2), mass density variation within the two powders appears to be small (<10%).
19. D. L. French, D. A. Edwards, R. W. Niven, J. Aerosol Sci. 27, 769 (1996).
20. W. I. Li et al., ibid., p. 1269.
21. 2+. A 100-μl sample was removed for particle counting using a hemacytometer. The remaining solution was mixed with 10 ml of 0.4 N NaOH. After incubation at 37°C for 12 hours, the fluorescence of each solution was measured (wavelengths of 554 nm excitation, 574 nm emission).
22. Lungs were lavaged immediately (5 to 10 min) after inhalation. A tracheal cannula was inserted and tied into place, and the airways were washed with 10-ml aliquots of HBSS. The lavage procedure was repeated until a total volume of 30 ml was collected. In the phagocytic cell experiments, lavage fluid was centrifuged and the cell pellets were resuspended in HBSS for counting, differentiation of cell types, and measurement of phagocytosis. Engulfment of particles by phagocytic cells was determined by counting microscopically the number of particles incorporated per cell in wet mounts and in fixed and stained cytocentrifuge preparations. Reported numbers are based on the wet-mount experiments; similar numbers were obtained using the stained cytocentrifuge preparations.
23. The lobes were placed in separate petri dishes containing 5 ml of HBSS. Each lobe was teased through a 60-mesh screen to dissociate the tissue and was then filtered through cotton gauze to remove tissue debris and connective tissue. The petri dish and gauze were washed with an additional 15 ml of HBSS to maximize microparticle collection. Each tissue preparation was centrifuged and resuspended in 2 ml of HBSS, and the particles were counted in a hemacytometer.
24. Rats were anesthetized and cannulated as described (17) and were force-ventilated for 10 to 20 min at 300 ml/min. Rats received two types of aerosols through the endotracheal tube. After the period of forced ventilation, necks were sutured and rats were revived within 1 to 2 hours. Blood samples (300 μl) were periodically withdrawn from the tail vein over a period of 2 to 6 days. These samples were mixed with assay buffer, centrifuged, and the supernatant examined for the presence of (endogenous and exogenous) insulin or testosterone using radioimmunoassays (ICN Pharmaceuticals, Costa Mesa, CA). Glucose was measured using a colorimetric assay (Sigma). Control studies involved subcutaneous injection of the same amount of powder as was inhaled. The particles were injected into the scruff of the neck.
25. D. A. Edwards, A. Ben-Jebria, J. Mintzes, J. Hanes, J. Hrkach, R. Langer, G. Caponetti, M. L. Eskew, D. Deaver, N. Lotan, data not shown.
26. S. Cohen et al., Pharm. Res. 8, 713 (1991).
27. subcutaneous) × 100, where AUC is area under the curve.
28. P. Colthorpe et al., Pharm. Res. 9, 764 (1992).
29. F. Komada et al., J. Pharm. Sci. 83, 863 (1994).
30. F. Y. Liu, Z. Shao, D. O. Kildsig, A. K. Mitra, Pharm. Res. 10, 228 (1993).
31. A. R. Gennaro, Ed., Remington: The Science and Practice of Pharmacy (Mack, Easton, PA, ed. 19, 1995).
32. H. Kawaguchi et al., Biomaterials 7, 61 (1986); L. J. Krenis and B. Strauss, Proc. Soc. Exp. Med. 107, 748 (1961); S. Rudt and R. H. Muller, J. Controlled Release 22, 263 (1992).
33. H. Kawaguchi et al., Biomaterials 7, 61 (1986); L. J. Krenis and B. Strauss, Proc. Soc. Exp. Med. 107, 748 (1961); S. Rudt and R. H. Muller, J. Controlled Release 22, 263 (1992).
34. H. Kawaguchi et al., Biomaterials 7, 61 (1986); L. J. Krenis and B. Strauss, Proc. Soc. Exp. Med. 107, 748 (1961); S. Rudt and R. H. Muller, J. Controlled Release 22, 263 (1992).
35. P. Le Corre et al., Int. J. Pharm. 107, 41 (1994).
36. M. Sacchetti and M. M. Van Oort, in (3), pp. 337-384.
37. J. W. Tom and P. G. Debenedetti, J. Aerosol Sci. 22, 555 (1991).
38. J. Heyder et al., ibid. 17, 811 (1986); D. A. Edwards, ibid. 26, 293 (1995).
39. J. Heyder et al., ibid. 17, 811 (1986); D. A. Edwards, ibid. 26, 293 (1995).
40. We thank J. Heidel and C. Perez de la Cruz for helpful technical assistance. Supported by an NSF CAREER Grant (D.E., J.M.) and NIH grants GM26698 (R.L.) and HD29125 (R.L., J.H.).